Pharmaceutical - Victoza, Research


Current filters:


Popular Filters

New Phase IIIa data further demonstrate benefits of liraglutide in obesity


Positive new data from the Phase IIIa SCALE Obesity and Prediabetes trial were presented today at Obesity…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearchSaxendaVictoza

ADA 2014: New data on Novo Nordisk’s IDegLira and Victoza

ADA 2014: New data on Novo Nordisk’s IDegLira and Victoza


A new Phase IIIa study shows that IDegLira, the once-daily single injection combination of Danish diabetes…

DiabetesIDegLiraNovo NordiskPharmaceuticalResearchVictoza

Data on Novo Nordisk's Victoza further supporting safety presented at expert workshop


Danish Insulin giant Novo Nordisk (NOV: N) presented data further supporting the safety of Victoza (liraglutide…

DiabetesNovo NordiskPharmaceuticalResearchVictoza

Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial


Danish insulin giant Novo Nordisk (NOV: N) has released headline results from a 56-week double-blind…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearchVictoza

Briefs: Elan tender offer; German drug price review; Daiichi Sankyo pays milestone


Ireland-based drugmaker Elan (NYSE: ELN) yesterday reported final results of its modified Dutch auction…

ActemraAmgenAnticalinBayerElanFinancialNovo NordiskPharmaceuticalPradaxaPricingProliaRegulationResearchRocheVictozaXarelto

New study shows Novo Nordisk's Victoza achieves 6% weight loss in type 2 diabetes patients


Danish insulin giant Novo Nordisk (NOVN: N) has released headline results from a 56-week, double-blind…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearchVictoza

Positive new Ph III data on Novo Nordisk's Victoza


Global Denmark-based insulin giant Novo Nordisk (NOV: N) yesterday reported data from two Phase IIIb…

DiabetesNovo NordiskPharmaceuticalResearchVictoza

Head-to-head trial of diabetes drugs Victoza and Bydureon yields mixed results


A direct, head-to-head comparison of two of the newer treatments available for type 2 diabetes yielded…

AmylinBydureonDiabetesEli LillyNovo NordiskPharmaceuticalResearchVictoza

Highlights of American Diabetes Association meeting


The weekend saw a flood of new data on diabetes drug candidates and currently approved treatments presented…

Boehringer IngelheimDegludecDiabetesEli LillyempagliflozinLyxumiaNovo NordiskPharmaceuticalResearchSanofiTradjentaVictoza

Positive Ph III results for Novo Nordisk's degludec; US advocacy calls for Victoza's withdrawal


Danish diabetes specialist Novo Nordisk (NOV: N) says that its investigational ultra-long-acting insulin…

DegludecDiabetesNorth AmericaNovo NordiskPharmaceuticalRegulationResearchVictoza

Victoza US label update includes superior efficacy over Januvia, says Novo Nordisk


The US Food and Drug Administration has approved an update to the product label for Victoza (liraglutide…

DiabetesJanuviaLevemirMerck & CoNorth AmericaNovo NordiskPharmaceuticalRegulationResearchVictoza

Back to top